During this presentation, Dr. Bankert discusses the optimal design of patient derived xenografts (PDX) to study cancer pathogenesis and responses to therapy. View this video to learn more about:
Professor, University of Buffalo, The State University of New York, School of Medicine and Biomedical Sciences
Dr. Bankert received his V.M.D. and Ph.D. degrees from the University of Pennsylvania where he studied B cell antigen receptors and the cell biology and immunohistochemistry of the humoral immune responses in mice and rabbits. He then moved to the Roswell Park Cancer Institute (RPCI) as a junior faculty member and advanced through a successful career at RPCI to become the Chairman of the Department of Immunology. While at RPCI, his work focused upon tumor immunology and immunotherapy. He later moved to University of Buffalo as a Professor of Microbiology and Immunology where his current research is focused upon novel lipid-mediated immune checkpoints in human tumor microenvironments. Dr. Bankert and his colleagues have designed and utilized many different models of patient derived xenografts for over 25 years to investigate the interaction between tumor cells and tumor infiltrating lymphocytes and to evaluate the efficacy of immunotherapeutic strategies for the treatment of cancer.
Registration is Open